tbuckley/cabot-search huggingface dataset:
Dynamics of human monocytes and airway macrophages during healthy aging and after transplant
Authors: Adam J. Byrne, Joseph E. Powell, Brendan J. O’Sullivan, Patricia P. Ogger, Ashley Hoffland, James Cook, Katie L. Bonner, Richard J. Hewitt, Simone Wolf, Poonam Ghai, Simone A. Walker, Samuel W. Lukowski, Philip L. Molyneaux, Sejal Saglani, Daniel C. Chambers, Toby M. Maher, Clare M. Lloyd
Journal: The Journal of Experimental Medicine (2020)

The ontogeny of airway macrophages (AMs) in human lung and their contribution to disease are poorly mapped out. In mice, aging is associated with an increasing proportion of peripherally, as opposed to perinatally derived AMs. We sought to understand AM ontogeny in human lung during healthy aging and after transplant. We characterized monocyte/macrophage populations from the peripheral blood and airways of healthy volunteers across infancy/childhood (2–12 yr), maturity (20–50 yr), and older adulthood (&amp;gt;50 yr). Single-cell RNA sequencing (scRNA-seq) was performed on airway inflammatory cells isolated from sex-mismatched lung transplant recipients. During healthy aging, the proportions of blood and bronchoalveolar lavage (BAL) classical monocytes peak in adulthood and decline in older adults. scRNA-seq of BAL cells from lung transplant recipients indicates that after transplant, the majority of AMs are recipient derived. These data show that during aging, the peripheral monocyte phenotype is consistent with that found in the airways and, furthermore, that the majority of human AMs after transplant are derived from circulating monocytes.
Using Unmanned Aircraft to Save Lives
Authors: Joseph R. Scalea
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
RCGP cancels fossil fuel conference at headquarters after backlash
Authors: Elisabeth Mahase
Journal: BMJ (2020)

The Royal College of General Practitioners (RCGP) has cancelled a conference run by Oil & Gas UK—a representative body for the oil and gas industry—which was due to be held at the college’s headquarters, after complaints raised by GPs.

The conference was due to be held on 29 January 2020 at 30 Euston Square, London. GPs and other medical professionals took to social media to express their concerns and to encourage others to sign a petition calling on the college to “withdraw their support for this conference.”1

The petition, which received over 1000 signatures, said that the college must ensure that its building was not used by organisations that “threaten public health by promoting the use of fossil fuels.” In response, the college has confirmed to The BMJ that the event has …
Prophylactic Topical Adapalene and Oral Minocycline for Panitumumab-Induced Skin Toxicity
Authors: T. Yanai, H. Hashimoto, N. Yamazaki, H. Yasui, G. Sakai, S. Akatsuka, K. Ogawa, S. Hirai, H. Yamamoto, T. Hamaguchi
Journal: Annals of Oncology (2012)
Phase III Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of Gefitinib versus Placebo in Esophageal Cancer Progressing after Chemotherapy, COG (Cancer Oesophagus Gefitinib)
Authors: D.R. Ferry, S.J. Dutton, W. Mansoor, J. Thompson, M. Harrison, H. Abbas, A. Dahle-Smith, A. Chatterjee, S. Falk, A. Garcia-Alonso, D.W. Fyfe, R. Hubner, T. Gamble, L. Peachey, M. Davoudianfar, S.R. Pearson, P. Julier, J. Jankowski, R. Midgely, R.D. Petty
Journal: Annals of Oncology (2012)
Association of Matrix Metalloproteinase 2 (MMP2) Plasma Level with Response and Survival in Patients Treated with Bevacizumab for Recurrent High Grade Glioma
Authors: E. Tabouret, F. Boudouresque, M. Barrié, M. Matta, C. Boucard, A. Loundou, M. Ouafik, O. Chinot
Journal: Annals of Oncology (2012)
Assessment of the Validity of the 2HELPS2B Score for Inpatient Seizure Risk Prediction
Authors: Aaron F. Struck, Mohammad Tabaeizadeh, Sarah E. Schmitt, Andres Rodriguez Ruiz, Christa B. Swisher, Thanujaa Subramaniam, Christian Hernandez, Safa Kaleem, Hiba A. Haider, Abbas Fodé Cissé, Monica B. Dhakar, Lawrence J. Hirsch, Eric S. Rosenthal, Sahar F. Zafar, Nicholas Gaspard, M. Brandon Westover
Journal: JAMA Neurology (2020)

<h3>Importance</h3> Seizure risk stratification is needed to boost inpatient seizure detection and to improve continuous electroencephalogram (cEEG) cost-effectiveness. 2HELPS2B can address this need but requires validation. <h3>Objective</h3> To use an independent cohort to validate the 2HELPS2B score and develop a practical guide for its use. <h3>Design, Setting, and Participants</h3> This multicenter retrospective medical record review analyzed clinical and EEG data from patients 18 years or older with a clinical indication for cEEG and an EEG duration of 12 hours or longer who were receiving consecutive cEEG at 6 centers from January 2012 to January 2019. 2HELPS2B was evaluated with the validation cohort using the mean calibration error (CAL), a measure of the difference between prediction and actual results. A Kaplan-Meier survival analysis was used to determine the duration of EEG monitoring to achieve a seizure risk of less than 5% based on the 2HELPS2B score calculated on first- hour (screening) EEG. Participants undergoing elective epilepsy monitoring and those who had experienced cardiac arrest were excluded. No participants who met the inclusion criteria were excluded. <h3>Main Outcomes and Measures</h3> The main outcome was a CAL error of less than 5% in the validation cohort. <h3>Results</h3> The study included 2111 participants (median age, 51 years; 1113 men [52.7%]; median EEG duration, 48 hours) and the primary outcome was met with a validation cohort CAL error of 4.0% compared with a CAL of 2.7% in the foundational cohort (<i>P</i> = .13). For the 2HELPS2B score calculated on only the first hour of EEG in those without seizures during that hour, the CAL error remained at less than 5.0% at 4.2% and allowed for stratifying patients into low- (2HELPS2B = 0; &lt;5% risk of seizures), medium- (2HELPS2B = 1; 12% risk of seizures), and high-risk (2HELPS2B, ≥2; risk of seizures, &gt;25%) groups. Each of the categories had an associated minimum recommended duration of EEG monitoring to achieve at least a less than 5% risk of seizures, a 2HELPS2B score of 0 at 1-hour screening EEG, a 2HELPS2B score of 1 at 12 hours, and a 2HELPS2B score of 2 or greater at 24 hours. <h3>Conclusions and Relevance</h3> In this study, 2HELPS2B was validated as a clinical tool to aid in seizure detection, clinical communication, and cEEG use in hospitalized patients. In patients without prior clinical seizures, a screening 1-hour EEG that showed no epileptiform findings was an adequate screen. In patients with any highly epileptiform EEG patterns during the first hour of EEG (ie, a 2HELPS2B score of ≥2), at least 24 hours of recording is recommended.
Phase I/II Study to Assess the Safety, Pharmacokinetics (PK) and Efficacy of Lorvotuzumab Mertansine (LM, IMGN901) in Combination with Carboplatin/Etoposide in Patients with Solid Tumors Including Small-Cell Lung Cancer (SCLC)
Authors: D.R. Spigel, J. Bendell, A.C. Mita, A. Argiris, C. Kurkjian, C.L. Hann, Z. Segota, R. Guild, R. Mastico, M.E. Guiterrez
Journal: Annals of Oncology (2012)
Deep cutaneous fungal infections in solid-organ transplant recipients
Authors: Agnès Galezowski, Julie Delyon, Laurence Le Cleach, Sarah Guégan, Emilie Ducroux, Alexandre Alanio, Diane Lastennet, Philippe Moguelet, Ali Dadban, Marie Thérèse Leccia, François Le Pelletier, Camille Francès, Céleste Lebbé, Stéphane Barete
Journal: Journal of the American Academy of Dermatology (2020)
Gefitinib (G) and Pemetrexed (Pem) as a First Line Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase II Study
Authors: N. Yoshimura, K. Matsuura, S. Mitsuoka, K. Asai, Y. Tochino, T. Kimura, M. Nakai, Y. Mitsukawa, K. Hirata, S. Kudoh
Journal: Annals of Oncology (2012)
Abstract 228: Epidemiology and Outcome of Out-Of-Hospital Cardiac Arrests in Kunming, Yunnan, China
Authors: Tao Yu, Tianen Zhou, Cai Wen
Journal: Circulation (2019)

Objective: The purpose of this study was to better understand the epidemiological features and outcomes of emergency medical service(EMS)-assessed out-of-hospital cardiac arrests(OHCAs) in Kunming,Yunnan,China. Methods: In this prospective study,datas were collected according to the Utstein style on all cases of OHCAs from January 2010 to December 2014 in urban areas covered by Kunming EMS system.The outcomes were analysed at four time points of survival: no return of spontaneous circulation (no-ROSC),return of spontaneous circulation (ROSC),survival to hospital admission, and survival to hospital discharge.The adjusted odds ratios(ORs) and 95% confidence intervals(CIs) for survival were calculated and adjusted for potential risk factors using stratified multivariable logistic regression analysis. Results: There were 3387 EMS-assessed OHCAs with cardiac aetiology from 2010 to 2014. The incidence of EMS-assessed OHCA with cardiac aetiology was 20.7 per 100,000 inhabitants per year. Of the 3387 EMS-assessed OHCAs with cardiac aetiology,the rates of ROSC,survival to admission and survival to discharge were 12.4%,3.5% and 0.9% respectively. There were only 73(2.2%)patients with initial rhythm of ventricular fibrillation(VF) or pulseless ventricular tachycardia(VT) observed in the EMS-assessed OHCAs with cardiac aetiology.There was no statistical difference among the five years in outcomes of OHCAs with cardiac aetiology.Younger age, bystander CPR,witnessed by EMS, OHCA with initial rhythm of VF/pulseless VT,shorter medication interval,and shorter response interval were associated with a higher rate of survival to discharge respectively. Conclusion: In the urban areas of Kunming covered by EMS system, survival outcome of OHCA was unsatisfactory.Improvements are required in every link of the chain of survival.
Rare germline variant contributions to myeloid malignancy susceptibility
Authors: Samuel T. Li, Janet Wang, Ruipeng Wei, Ruqi Shi, Vera Adema, Yasunobu Nagata, Cassandra M. Kerr, Teodora Kuzmanovic, Bartlomiej Przychodzen, Francesc Sole, Jaroslaw P. Maciejewski, Thomas LaFramboise
Journal: Leukemia (2020)
Clinical Significance of Surgery for Gastric Submucosal Tumors with Size Enlargement During Watchful Waiting Period
Authors: Y. Miyazaki, K. Nakajima, Y. Kurokawa, T. Takahashi, S. Takaguchi, H. Miyata, M. Yamasaki, T. Nishida, M. Mori, Y. Doki
Journal: Annals of Oncology (2012)
Abstract 481: Cardiopulmonary Resuscitation: The Effect of Fatigue on Professional Rescuers During Continuous Chest Compressions
Authors: Olibhear McAlister, Adam Harvey, Hannah Torney, Ben McCartney, Laura Davis, Pamela Owens, Ahamed H Idris
Journal: Circulation (2019)

Introduction: It is reported that quality of chest compressions (CC) during cardiopulmonary resuscitation (CPR) for both professional and non-professional rescuers often do not meet guideline requirements. Devices which provide feedback on the quality of CCs are designed to reduce the incidence of suboptimal compressions and promote the administration of effective CCs. Objective: This analysis investigates the effect of CPR duration on the performance of continuous CCs delivered by professional rescuers. Methods: Data were collected from a first responder group based in Texas, USA. Responders were instructed to use a CPR depth feedback device (Laerdal CPRmeter) and an automatic external defibrillator (AED; HeartSine SAM 350P) when attending sudden cardiac arrest events. The AED was configured with a shock protocol separated by 2-minute episodes of CPR and rescuer CC depth and rate were guided by the CPR depth feedback device. CC depth and rate data were processed for 174 patient events. Each CPR episode was divided into 4-analysis windows, 30-seconds in duration. Mean CC depth and rate data was calculated for each window. There were 1433 observations of CC depth and rate available for analysis across 414 CPR episodes. The data was fitted by a multiple linear regression model to assess the effect of CPR duration on CC performance. Results: The mean CC depth at the beginning of an event was 49.01 +/-0.51 mm. CC depth decreased by 0.82 mm, for each passing 30-second interval (p &lt; 0.001). The mean CC rate at the beginning of an event was 111.17 +/- 0.33 compression per minute (CPM). No significant difference was observed between CC rate and duration of continuous CCs (p = 0.896) however there was a significant increase in CC rate observed of 0.408 CPM for each elapsed 2-minute CPR episode (p = 0.011). Conclusion: A reduction in CC depth was observed within each CPR episode, which may be indicative of fatigue during continuous CCs. Although a reduction of 3.28 mm throughout a 2-minute period of CPR may be clinically insignificant, this effect was observed within a trained rescuer group with CPR feedback. Further research is required to assess the effect of fatigue in non-professional responders.
Mesothelin and Individual Characteristics in a Cohort of Asbestos Exposed Workers
Authors: M. Mencoboni, L.A. Michelazzi, A. Cioè, A. Bruzzone, L. Delcorso, V. Mortara, P. Marroni, G. Dini, S. Marcenaro, F. Spigno
Journal: Annals of Oncology (2012)
Association of BMI, Fitness, and Mortality in Patients With Diabetes: Evaluating the Obesity Paradox in the Henry Ford Exercise Testing Project (FIT Project) Cohort
Authors: Seamus P. Whelton, Paul A. McAuley, Zeina Dardari, Olusola A. Orimoloye, Clinton A. Brawner, Jonathan K. Ehrman, Steven J. Keteyian, Mouaz Al-Mallah, Michael J. Blaha
Journal: Diabetes Care (2020)

OBJECTIVE To determine the effect of fitness on the association between BMI and mortality among patients with diabetes. RESEARCH DESIGN AND METHODS We identified 8,528 patients with diabetes (self-report, medication use, or electronic medical record diagnosis) from the Henry Ford Exercise Testing Project (FIT Project). Patients with a BMI &amp;lt;18.5 kg/m2 or cancer were excluded. Fitness was measured as the METs achieved during a physician-referred treadmill stress test and categorized as low (&amp;lt;6), moderate (6–9.9), or high (≥10). Adjusted hazard ratios for mortality were calculated using standard BMI (kilograms per meter squared) cutoffs of normal (18.5–24.9), overweight (25–29.9), and obese (≥30). Adjusted splines centered at 22.5 kg/m2 were used to examine BMI as a continuous variable. RESULTS Patients had a mean age of 58 ± 11 years (49% women) with 1,319 deaths over a mean follow-up of 10.0 ± 4.1 years. Overall, obese patients had a 30% lower mortality hazard (P &amp;lt; 0.001) compared with normal-weight patients. In adjusted spline modeling, higher BMI as a continuous variable was predominantly associated with a lower mortality risk in the lowest fitness group and among patients with moderate fitness and BMI ≥30 kg/m2. Compared with the lowest fitness group, patients with higher fitness had an ∼50% (6–9.9 METs) and 70% (≥10 METs) lower mortality hazard regardless of BMI (P &amp;lt; 0.001). CONCLUSIONS Among patients with diabetes, the obesity paradox was less pronounced for patients with the highest fitness level, and these patients also had the lowest risk of mortality.
Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007)
Authors: A.T. Shaw, D.W. Kim, K. Nakagawa, T. Seto, L. Crinò, M. Ahn, T. De Pas, B. Besse, B. Solomon, F.H. Blackhall, Y. Wu, M. Thomas, K.J. O'Byrne, D. Moro-Sibilot, R. Camidge, V. Hirsh, T.S.K. Mok, V. Tassell, A. Polli, P. Jänne
Journal: Annals of Oncology (2012)
Shared decision making: improving doctor-patient communication
Authors: Pål Gulbrandsen
Journal: BMJ (2020)

Maskrey asks why progress in shared decision making has been slow.1 Medicine has ignored insights from conversation analysis and sociolinguistics. Communication skills training is delivered as prescriptions, without basic teaching of personal dynamics in asymmetric talks. This is like teaching how to prescribe drugs without teaching pharmacology.

The complexity of shared decision making is under-rated. Doing it as …
The panorama in diagnoses of severe combined immunodeficiency begins to change in Brazil
Authors: Juliana Mazzucchelli, Carolina Sanchez Aranda, Mariana Gouveia-Pereira, Lucila Akune Barreiros, Beatriz Tavares Costa Carvalho, Antonio Condino-Neto, Maria Isabel de Moraes-Pinto
Journal: Journal of Allergy and Clinical Immunology (2020)
Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors
Authors: E. Pros, M. Saigi, D. Alameda, G. Gomez-Mariano, B. Martinez-Delgado, J.J. Alburquerque-Bejar, J. Carretero, R. Tonda, A. Esteve-Codina, I. Catala, R. Palmero, M. Jove, C. Lazaro, A. Patiño-Garcia, I. Gil-Bazo, S. Verdura, A. Teulé, J. Torres-Lanzas, D. Sidransky, N. Reguart, R. Pio, O. Juan-Vidal, E. Nadal, E. Felip, L.M. Montuenga, M. Sanchez-Cespedes
Journal: Annals of Oncology (2020)
Non Pegylated Liposomal Doxorubicin Beyond the First Line Treatment of Metastatic Breast Cancer Patients: A Retrospective Analysis
Authors: S. Bernhard, L. Mansi, V. Nerich, C.B. Villanueva, E. Dobi, H. Almotlak, F. Bazan, L. Chaigneau, L. Cals, X. Pivot
Journal: Annals of Oncology (2012)
Analysis of time from initial imaging study to definitive surgical diagnosis in patients with epithelial ovarian malignancies.
Authors: Thomas Bickley, Eericca Clegg, John Nash, Xiaowei (Sherry) Yan, Radhika Gogoi
Journal: Journal of Clinical Oncology (2012)

e15536 Background: It is well established that women diagnosed with advanced stage ovarian cancer have a significantly lower five-year survival rate. Often multiple imaging modalities are used in the initial evaluation. This is costly, often unnecessary, and may be a contributing factor to a delay in diagnosis. We sought to evaluate the time from initial imaging study to diagnosis. Methods: After IRB approval, a retrospective chart review was performed utilizing data from the electronic medical record at an integrated health care system. All patients who underwent surgery with a diagnosis of primary peritoneal, ovarian, or fallopian tube cancer between 7/2006 and 8/2011 were included. Data collected included age at time of surgery, number and dates of imaging studies performed within 180 days prior to surgery, primary cancer site, stage, and histology. Patients were excluded for recurrent disease, studies without dates, or imaging studies performed greater than 180 days prior to diagnosis. Statistical analysis was performed using the Cox Proportional Model. Results: A total of 146 patients were included in the study. The average number of imaging studies was 1.7 and the average time to diagnosis from initial imaging was 33.5 days. Time to diagnosis was shorter if patients ever had a CT scan (29.3 vs 73.3 days; P&lt;0.001), and longer if patients ever had an ultrasound (40.4 vs 27.8 days; P=0.02). There was no difference in the overall number of imaging studies performed when controlling for stage &lt;3C vs &gt;3C. However, time to diagnosis was significantly less (29.1 vs 45.1 days; P=0.01) for more advanced stage disease. There was no difference in time to diagnosis or overall number of imaging studies performed when controlling for primary cancer site or age. Conclusions: The data suggest that performing a CT scan as the only imaging modality results in a significantly shorter time to diagnosis than when ultrasonography is included in the initial evaluation. Of patients who initially got an ultrasound most ultimately went on to have a CT scan, likely increasing the interval to diagnosis. We suggest that implementing an adnexal mass algorithm may allow patients quicker access to definitive diagnosis and treatment.
Problems With Clinical Application of Low-Dose Vasopressin for Traumatic Hemorrhagic Shock—Reply
Authors: Carrie A. Sims
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral neuropathy
Authors: A.J.M. Beijers, C.S. Bonhof, F. Mols, J. Ophorst, J. de Vos-Geelen, E.M.G. Jacobs, L.V. van de Poll-Franse, G. Vreugdenhil
Journal: Annals of Oncology (2020)
Docetaxel, Cisplatin and Fluorouracil as Perioperative Chemotherapy in Resectable Gastroesophageal Carcinoma: a Retrospective Analysis
Authors: F. Fiteni, Z. Lakkis, T. Nguyen, C. Borg, B. Benzidane, V. Nerich, B. Heyd, X. Pivot, C.H.S. Kim
Journal: Annals of Oncology (2012)